Background: Dengue infection is a major public health problem in Thailand where provincial incidence rates is reported up to 698/100,000 person years. In preparation for the upcoming dengue vaccine, comprehensive data are essential for decision-making for vaccine introduction.
Methods: A comprehensive study sponsored by DVI composed of a passive facility-based surveillance; sero-survey; a healthcare utilization survey; a cost-of-illness (COI) survey; and a vaccine willingness-to-pay (WTP) survey is conducted to determine the burden of dengue in Bang Phae district of Ratchaburi province. In the surveillance, febrile patients between 1-55 years-of-age are evaluated for dengue infection. Among dengue-confirmed cases, the COI survey estimates the economic burden of disease. For the sero-survey, 2000 randomly selected residents are enrolled to determine sero-conversion rate. The WTP and the healthcare utilization surveys assess private demand of dengue vaccines and the proportion of febrile cases missed by the passive surveillance.
Results: During October to December 2011, 108 patients were enrolled in passive fever surveillance in Bang Phae Community Hospital. Among 70 pairs of acute/convalescent blood samples examined using ELISA, 15 cases (21%) of acute dengue infection were found, including 3 primary and 12 secondary infections. There were 8 dengue-confirmed enrollees in the COI survey. Preliminary analysis showed that the private direct out-of-pocket cost per dengue case is fairly high (THB 1,123). The serosurvey will be launched in April 2012, before the dengue transmission peak. Prior to the WTP survey, focus group discussions and a pilot test (40 household interviews) were conducted. It was found that almost all respondents believe that dengue vaccines should be used and that the government should pay for children's vaccinations and cited price as the most important determinant of demand, followed by efficacy. All respondents stated they would purchase dengue vaccines for their youngest child if it is 100THB per dose.
Conclusion:
The data generated will be used to build a comprehensive national investment case of dengue vaccine in Thailand, a likely early adopter country of dengue vaccines. The investment case will be used as models for other countries in the respective regions to facilitate accelerated development and introduction of safe and effective dengue vaccines. Background: The incidence of invasive Salmonella bloodstream infections in sub-Saharan Africa remains largely unknown. Comparable data in this region are paramount for public health experts to make evidence-based decisions on the introduction of vaccines against S. Typhi and non-typhoidal Salmonella (NTS) infections. Consequently, the International Vaccine Institute (IVI) has established standardized surveillance for invasive bloodstream infections at ten sentinel sites in sub-Saharan Africa, including Ghana, to gather these data. Information on two year surveillance to estimate the burden of invasive Salmonella infections in Ghana are summarized in this abstract.
Methods: The surveillance site in Ghana is located in the rural town of Agogo (70km east of Kumasi) with an estimated population
